Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 402Colorectal Neoplasms 317Rectal Neoplasms 235Stomach Neoplasms 209Pancreatic Neoplasms 137Neoplasm Metastasis 123Colonic Neoplasms 94Neoplasms 86Triple Negative Breast Neoplasms 64Esophageal Neoplasms 57Biliary Tract Neoplasms 39Nasopharyngeal Carcinoma 37Cholangiocarcinoma 31Adenocarcinoma 31Carcinoma, Hepatocellular 30Gallbladder Neoplasms 29Carcinoma, Non-Small-Cell Lung 21Bile Duct Neoplasms 21Locally Advanced Rectal Cancer 20Adenocarcinoma Of Esophagus 20Squamous Cell Carcinoma of Head and Neck 19Brain Neoplasms 19Gastrointestinal Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Liver Neoplasms 17Head and Neck Neoplasms 17Esophageal Squamous Cell Carcinoma 17Colorectal Cancer Metastatic 15Ovarian Neoplasms 14Breast Neoplasms, Male 14

Interventions

eribulin 1disitamab vedotin 1RC48 antibody 1Paclitaxel 1Gemcitabine 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-low Breast Cancer × Capecitabine × Clear all
NCT06957886 2026-01-21

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
566 enrolled
Breast

HER2-low Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡